Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms

References

• Swerdlow S, Campo E, Harris N, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer; 2008.
   Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390.
   PubMed Web of Science ®Google Scholar
• The non-Hodgkin’s lymphoma classification project: a clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood. 1997;89(11):3909–3918.
   PubMed Web of Science ®Google Scholar
• Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–4130.
   PubMed Web of Science ®Google Scholar
• Armitage JO. The aggressive peripheral T-cell lymphomas: 2015. Am J Hematol. 2015;90(7):665–673.
   PubMed Web of Science ®Google Scholar
• Jaffe ES. Anaplastic large cell lymphoma: the shifting sands of diagnostic hematopathology. Mod Pathol. 2001;14(3):219–228.
   PubMed Web of Science ®Google Scholar
• Webb TR, Slavish J, George RE, et al. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer Ther. 2009;9(3):331–356.
   PubMed Web of Science ®Google Scholar
• Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science. 1995;267(5196):316–317.
   PubMed Web of Science ®Google Scholar
• Marzec M, Kasprzycka M, Liu X, et al. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway. Oncogene. 2007;26(38):5606–5614.
   PubMed Web of Science ®Google Scholar
• Ma Z, Cools J, Marynen P, et al. Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis. Blood. 2000;95(6):2144–2149.
   PubMed Web of Science ®Google Scholar
• Feldman AL, Vasmatzis G, Asmann YW, et al. Novel TRAF1-ALK fusion identified by deep RNA sequencing of anaplastic large cell lymphoma. Genes Chromosomes Cancer. 2013;52(11):1097–1102.
   PubMed Web of Science ®Google Scholar
• Falini B, Pileri S, Zinzani PL, et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood. 1999;93(8):2697–2706.
   PubMed Web of Science ®Google Scholar
• Parrilla Castellar ER, Jaffe ES, Said JW, et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood. 2014;124(9):1473–1480.
   PubMed Web of Science ®Google Scholar
• Feldman AL, Dogan A, Smith DI, et al. Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood. 2011;117(3):915–919.
   PubMed Web of Science ®Google Scholar
• Huang CY, Tan TH. DUSPs, to MAP kinases and beyond. Cell Biosci. 2012;2(1):24.
   PubMed Web of Science ®Google Scholar
• Melard P, Idrissi Y, Andrique L, et al. Molecular alterations and tumor suppressive function of the DUSP22 (dual specificity phosphatase 22) gene in peripheral T-cell lymphoma subtypes. Oncotarget. 2016;7(42):68734–68748.
   PubMed Web of Science ®Google Scholar
• Vasmatzis G, Johnson SH, Knudson RA, et al. Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood. 2012;120(11):2280–2289.
   PubMed Web of Science ®Google Scholar
• Graziano V, De Laurenzi V. Role of p63 in cancer development. Biochim Biophys Acta. 2011;1816(1):57–66.
   PubMed Web of Science ®Google Scholar
• Crescenzo R, Abate F, Lasorsa E, et al. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell. 2015;27(4):516–532.
   PubMed Web of Science ®Google Scholar
• Laurent C, Delas A, Gaulard P, et al. Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes. Ann Oncol. 2016;27(2):306–314.
   PubMed Web of Science ®Google Scholar
• Aladily TN, Medeiros LJ, Amin MB, et al. Anaplastic large cell lymphoma associated with breast implants: a report of 13 cases. Am J Surg Pathol. 2012;36(7):1000–1008.
   PubMed Web of Science ®Google Scholar
• Clemens MW, Medeiros LJ, Butler CE, et al. Complete surgical excision is essential for the management of patients with breast implant-associated anaplastic large-cell lymphoma. J Clin Oncol. 2016;34(2):160–168.
   PubMed Web of Science ®Google Scholar
• Miranda RN, Aladily TN, Prince HM, et al. Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. J Clin Oncol. 2014;32(2):114–120.
   PubMed Web of Science ®Google Scholar
• Hapgood G, Pickles T, Sehn LH, et al. Outcome of primary cutaneous anaplastic large cell lymphoma: a 20-year British Columbia Cancer Agency experience. Br J Haematol. 2017;176(2):234–240.
   PubMedGoogle Scholar
• Wieser I, Oh CW, Talpur R, et al. Lymphomatoid papulosis: treatment response and associated lymphomas in a study of 180 patients. J Am Acad Dermatol. 2016;74(1):59–67.
   PubMed Web of Science ®Google Scholar
• Karai LJ, Kadin ME, Hsi ED, et al. Chromosomal rearrangements of 6p25.3 define a new subtype of lymphomatoid papulosis. Am J Surg Pathol. 2013;37(8):1173–1181.
   PubMed Web of Science ®Google Scholar
• Wada DA, Law ME, Hsi ED, et al. Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies. Mod Pathol. 2011;24(4):596–605.
   PubMed Web of Science ®Google Scholar
• Dogan A, Attygalle AD, Kyriakou C. Angioimmunoblastic T-cell lymphoma. Br J Haematol. 2003;121(5):681–691.
   PubMed Web of Science ®Google Scholar
• Jaffe ES, Nicolae A, Pittaluga S. Peripheral T-cell and NK-cell lymphomas in the WHO classification: pearls and pitfalls. Mod Pathol. 2013;26(Suppl 1):S71–S87.
   PubMed Web of Science ®Google Scholar
• de Leval L, Rickman DS, Thielen C, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood. 2007;109(11):4952–4963.
   PubMed Web of Science ®Google Scholar
• Sakata-Yanagimoto M, Enami T, Yoshida K, et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet. 2014;46(2):171–175.
   PubMed Web of Science ®Google Scholar
• Cairns RA, Iqbal J, Lemonnier F, et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood. 2012;119(8):1901–1903.
   PubMed Web of Science ®Google Scholar
• Lemonnier F, Couronné L, Parrens M, et al. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. Blood. 2012;120(7):1466–1469.
   PubMed Web of Science ®Google Scholar
• Tan BT, Warnke RA, Arber DA. The frequency of B- and T-cell gene rearrangements and Epstein–Barr virus in T-cell lymphomas: a comparison between angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified with and without associated B-cell proliferations. J Mol Diagn. 2006;8(4):466–475; quiz 527.
   PubMed Web of Science ®Google Scholar
• Balagué O, Martínez A, Colomo L, et al. Epstein–Barr virus negative clonal plasma cell proliferations and lymphomas in peripheral T-cell lymphomas: a phenomenon with distinctive clinicopathologic features. Am J Surg Pathol. 2007;31(9):1310–1322.
   PubMed Web of Science ®Google Scholar
• Nicolae A, Pittaluga S, Venkataraman G, et al. Peripheral T-cell lymphomas of follicular T-helper cell derivation with Hodgkin/Reed–Sternberg cells of B-cell lineage: both EBV-positive and EBV-negative variants exist. Am J Surg Pathol. 2013;37(6):816–826.
   PubMed Web of Science ®Google Scholar
• Moroch J, Copie-Bergman C, de Leval L, et al. Follicular peripheral T-cell lymphoma expands the spectrum of classical Hodgkin lymphoma mimics. Am J Surg Pathol. 2012;36(11):1636–1646.
   PubMed Web of Science ®Google Scholar
• Iqbal J, Wright G, Wang C, et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood. 2014;123(19):2915–2923.
   PubMed Web of Science ®Google Scholar
• Chang H-D, Helbig C, Tykocinski L, et al. Expression of IL-10 in Th memory lymphocytes is conditional on IL-12 or IL-4, unless the IL-10 gene is imprinted by GATA-3. Eur J Immunol. 2007;37(3):807–817.
   PubMed Web of Science ®Google Scholar
• Cook KD, Miller J. TCR-dependent translational control of GATA-3 enhances Th2 differentiation. J Immunol. 2010;185(6):3209–3216.
   PubMed Web of Science ®Google Scholar
• Shoemaker J, Saraiva M, O’Garra A. GATA-3 directly remodels the IL-10 locus independently of IL-4 in CD4+ T cells. J Immunol. 2006;176(6):3470–3479.
   PubMed Web of Science ®Google Scholar
• Wang T, Feldman AL, Wada DA, et al. GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features. Blood. 2014;123(19):3007–3015.
   PubMed Web of Science ®Google Scholar
• Palomero T, Couronné L, Khiabanian H, et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet. 2014;46(2):166–170.
   PubMed Web of Science ®Google Scholar
• Deleeuw RJ, Zettl A, Klinker E, et al. Whole-genome analysis and HLA genotyping of enteropathy-type T-cell lymphoma reveals 2 distinct lymphoma subtypes. Gastroenterology. 2007;132(5):1902–1911.
   PubMed Web of Science ®Google Scholar
• Delabie J, Holte H, Vose JM, et al. Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project. Blood. 2011;118(1):148–155.
   PubMed Web of Science ®Google Scholar
• Tan S-Y, Ooi A-S, Ang M-K, et al. Nuclear expression of MATK is a novel marker of type II enteropathy-associated T-cell lymphoma. Leukemia. 2011;25(3):555–557.
   PubMed Web of Science ®Google Scholar
• Tomita S, Kikuti YY, Carreras J, et al. Genomic and immunohistochemical profiles of enteropathy-associated T-cell lymphoma in Japan. Mod Pathol. 2015;28(10):1286–1296.
   PubMed Web of Science ®Google Scholar
• Zettl A, Ott G, Makulik A, et al. Chromosomal gains at 9q characterize enteropathy-type T-cell lymphoma. Am J Pathol. 2002;161(5):1635–1645.
   PubMed Web of Science ®Google Scholar
• Chan JK, Chan AC, Cheuk W, et al. Type II enteropathy-associated T-cell lymphoma: a distinct aggressive lymphoma with frequent gammadelta T-cell receptor expression. Am J Surg Pathol. 2011;35(10):1557–1569.
   PubMed Web of Science ®Google Scholar
• Küçük C, Jiang B, Hu X, et al. Activating mutations of STAT5B and STAT3 in lymphomas derived from gammadelta-T or NK cells. Nat Commun. 2015;6:6025.
   PubMed Web of Science ®Google Scholar
• Roberti A, Dobay MP, Bisig B, et al. Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations. Nat Commun. 2016;7:12602.
   PubMed Web of Science ®Google Scholar
• Pfister SX, Markkanen E, Jiang Y, et al. Inhibiting WEE1 selectively kills histone H3K36me3-deficient cancers by dNTP starvation. Cancer Cell. 2015;28(5):557–568.
   PubMed Web of Science ®Google Scholar
• Perry AM, Warnke RA, Hu Q, et al. Indolent T-cell lymphoproliferative disease of the gastrointestinal tract. Blood. 2013;122(22):3599–3606.
   PubMed Web of Science ®Google Scholar
• Virmani P, Jawed S, Myskowski PL, et al. Long-term follow-up and management of small and medium-sized CD4+ T cell lymphoma and CD8+ lymphoid proliferations of acral sites: a multicenter experience. Int J Dermatol. 2016;55(11):1248–1254.
   PubMed Web of Science ®Google Scholar
• Garcia-Herrera A, Colomo L, Camos M, et al. Primary cutaneous small/medium CD4+ T-cell lymphomas: a heterogeneous group of tumors with different clinicopathologic features and outcome. J Clin Oncol. 2008;26(20):3364–3371.
   PubMed Web of Science ®Google Scholar
• Beltraminelli H, Leinweber B, Kerl H, et al. Primary cutaneous CD4+ small-/medium-sized pleomorphic T-cell lymphoma: a cutaneous nodular proliferation of pleomorphic T lymphocytes of undetermined significance? A study of 136 cases. Am J Dermatopathol. 2009;31(4):317–322.
   PubMed Web of Science ®Google Scholar
• Petrella T, Maubec E, Cornillet-Lefebvre P, et al. Indolent CD8-positive lymphoid proliferation of the ear: a distinct primary cutaneous T-cell lymphoma? Am J Surg Pathol. 2007;31(12):1887–1892.
   PubMed Web of Science ®Google Scholar
• Bajor-Dattilo EB, Pittaluga S, Jaffe ES. Pathobiology of T-cell and NK-cell lymphomas. Best Pract Res Clin Haematol. 2013;26(1):75–87.
   PubMed Web of Science ®Google Scholar
• Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768–3785.
   PubMed Web of Science ®Google Scholar
• Guitart J, Weisenburger DD, Subtil A, et al. Cutaneous γδ T-cell lymphomas: a spectrum of presentations with overlap with other cytotoxic lymphomas. Am J Surg Pathol. 2012;36(11):1656–1665.
   PubMed Web of Science ®Google Scholar
• Toro JR, Liewehr DJ, Pabby N, et al. Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. Blood. 2003;101(9):3407–3412.
   PubMed Web of Science ®Google Scholar
• Quintanilla-Martinez L, Kumar S, Fend F, et al. Fulminant EBV(+) T-cell lymphoproliferative disorder following acute/chronic EBV infection: a distinct clinicopathologic syndrome. Blood. 2000;96(2):443–451.
   PubMed Web of Science ®Google Scholar
• Quintanilla-Martinez L, Ridaura C, Nagl F, et al. Hydroa vacciniforme-like lymphoma: a chronic EBV+ lymphoproliferative disorder with risk to develop a systemic lymphoma. Blood. 2013;122(18):3101–3110.
   PubMed Web of Science ®Google Scholar
• Yang Y-Q, Fan L, Wang L, et al. Systemic lymphoma arising from hydroa vacciniforme-like lymphoma: report of two cases with review of literature. Int J Clin Exp Pathol. 2014;7(9):6403–6408.
   PubMed Web of Science ®Google Scholar
• Loughran TP Jr. Clonal diseases of large granular lymphocytes. Blood. 1993;82(1):1–14.
   PubMed Web of Science ®Google Scholar
• Sokol L, Loughran TP Jr. Large granular lymphocyte leukemia. Oncologist. 2006;11(3):263–273.
   PubMed Web of Science ®Google Scholar
• Zhang D, Loughran TP Jr. Large granular lymphocytic leukemia: molecular pathogenesis, clinical manifestations, and treatment. Hematol Am Soc Hematol Educ Program. 2012;2012:652–659.
   PubMedGoogle Scholar
• Koskela HL, Eldfors S, Ellonen P, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med. 2012;366(20):1905–1913.
   PubMed Web of Science ®Google Scholar
• Jerez A, Clemente MJ, Makishima H, et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood. 2012;120(15):3048–3057.
   PubMed Web of Science ®Google Scholar
• Rajala HL, Eldfors S, Kuusanmäki H, et al. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood. 2013;121(22):4541–4550.
   PubMed Web of Science ®Google Scholar
• Nicolae A, Xi L, Pittaluga S, et al. Frequent STAT5B mutations in gammadelta hepatosplenic T-cell lymphomas. Leukemia. 2014;28(11):2244–2248.
   PubMed Web of Science ®Google Scholar
• Loughran TP Jr, Zickl L, Olson TL, et al. Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). Leukemia. 2015;29(4):886–894.
   PubMed Web of Science ®Google Scholar
• Diehl V, Sextro M, Franklin J, et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin’s disease and lymphocyte-rich classical Hodgkin’s disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin’s Disease. J Clin Oncol. 1999;17(3):776–783.
   PubMed Web of Science ®Google Scholar
• Shimabukuro-Vornhagen A, Haverkamp H, Engert A, et al. Lymphocyte-rich classical Hodgkin’s lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin’s Study Group trials. J Clin Oncol. 2005;23(24):5739–5745.
   PubMed Web of Science ®Google Scholar
• Nam-Cha SH, Montes-Moreno S, Salcedo MT, et al. Lymphocyte-rich classical Hodgkin’s lymphoma: distinctive tumor and microenvironment markers. Mod Pathol. 2009;22(8):1006–1015.
   PubMed Web of Science ®Google Scholar
• Savage KJ, Mottok A, Fanale M. Nodular lymphocyte-predominant Hodgkin lymphoma. Semin Hematol. 2016;53(3):190–202.
   PubMed Web of Science ®Google Scholar
• Hansmann ML, Stein H, Dallenbach F, et al. Diffuse lymphocyte-predominant Hodgkin’s disease (diffuse paragranuloma). A variant of the B-cell-derived nodular type. Am J Pathol. 1991;138(1):29–36.
   PubMed Web of Science ®Google Scholar
• Braeuninger A, Küppers R, Strickler JG, et al. Hodgkin and Reed–Sternberg cells in lymphocyte predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells. Proc Natl Acad Sci U S A. 1997;94(17):9337–9342.
   PubMed Web of Science ®Google Scholar
• Nicholas DS, Harris S, Wright DH. Lymphocyte predominance Hodgkin’s disease – an immunohistochemical study. Histopathology. 1990;16(2):157–165.
   PubMed Web of Science ®Google Scholar
• Fan Z, Natkunam Y, Bair E, et al. Characterization of variant patterns of nodular lymphocyte predominant Hodgkin lymphoma with immunohistologic and clinical correlation. Am J Surg Pathol. 2003;27(10):1346–1356.
   PubMed Web of Science ®Google Scholar
• Hartmann S, Eichenauer DA, Plütschow A, et al. The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood. 2013;122(26):4246–4252.
   PubMed Web of Science ®Google Scholar
• Rüdiger T, Gascoyne RD, Jaffe ES, et al. Workshop on the relationship between nodular lymphocyte predominant Hodgkin’s lymphoma and T cell/histiocyte-rich B cell lymphoma. Ann Oncol. 2002;13(Suppl 1):44–51.
   PubMed Web of Science ®Google Scholar
• Boudová L, Torlakovic E, Delabie J, et al. Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma. Blood. 2003;102(10):3753–3758.
   PubMed Web of Science ®Google Scholar
• Hartmann S, Döring C, Vucic E, et al. Array comparative genomic hybridization reveals similarities between nodular lymphocyte predominant Hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma. Br J Haematol. 2015;169(3):415–422.
   PubMed Web of Science ®Google Scholar
• Xing KH, Connors JM, Lai A, et al. Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis. Blood. 2014;123(23):3567–3573.
   PubMed Web of Science ®Google Scholar
• Hartmann S, Döring C, Jakobus C, . Nodular lymphocyte predominant Hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma – endpoints of a spectrum of one disease? PLoS One. 2013;8(11):e78812.
   PubMed Web of Science ®Google Scholar
• Advani RH, Horning SJ, Hoppe RT, et al. Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. J Clin Oncol. 2014;32(9):912–918.
   PubMed Web of Science ®Google Scholar
• Ratei R, Hummel M, Anagnostopoulos I, et al. Common clonal origin of an acute B-lymphoblastic leukemia and a Langerhans’ cell sarcoma: evidence for hematopoietic plasticity. Haematologica. 2010;95(9):1461–1466.
   PubMed Web of Science ®Google Scholar
• Chen W, Jaffe R, Zhang L, et al. Langerhans cell sarcoma arising from chronic lymphocytic lymphoma/small lymphocytic leukemia: lineage analysis and BRAF V600E mutation study. N Am J Med Sci. 2013;5(6):386–391.
   PubMedGoogle Scholar
• Shao H, Xi L, Raffeld M, et al. Clonally related histiocytic/dendritic cell sarcoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a study of seven cases. Mod Pathol. 2011;24(11):1421–1432.
   PubMed Web of Science ®Google Scholar
• Feldman AL, Arber DA, Pittaluga S, et al. Clonally related follicular lymphomas and histiocytic/dendritic cell sarcomas: evidence for transdifferentiation of the follicular lymphoma clone. Blood. 2008;111(12):5433–5439. PMCID: 2424145.
   PubMed Web of Science ®Google Scholar
• Stoecker MM, Wang E. Histiocytic/dendritic cell transformation of B-cell neoplasms: pathologic evidence of lineage conversion in differentiated hematolymphoid malignancies. Arch Pathol Lab Med. 2013;137(6):865–870.
   PubMed Web of Science ®Google Scholar
• Feldman AL, Minniti C, Santi M, et al. Histiocytic sarcoma after acute lymphoblastic leukaemia: a common clonal origin. Lancet Oncol. 2004;5(4):248–250.
   PubMed Web of Science ®Google Scholar
• Feldman AL, Berthold F, Arceci R, et al. Clonal relationship between precursor T-lymphoblastic leukaemia/lymphoma and Langerhans-cell histiocytosis. Lancet Oncol. 2005;6(6):435–437.
   PubMed Web of Science ®Google Scholar
• West DS, Dogan A, Quint PS, et al. Clonally related follicular lymphomas and langerhans cell neoplasms: expanding the spectrum of transdifferentiation. Am J Surg Pathol. 2013;37(7):978–986.
   PubMed Web of Science ®Google Scholar
• Diamond EL, Dagna L, Hyman DM, et al. Consensus guidelines for the diagnosis and clinical management of Erdheim–Chester disease. Blood. 2014;124(4):483–492.
   PubMed Web of Science ®Google Scholar
• Laurencikas E, Gavhed D, Stålemark H, et al. Incidence and pattern of radiological central nervous system Langerhans cell histiocytosis in children: a population based study. Pediatr Blood Cancer. 2011;56(2):250–257.
   PubMed Web of Science ®Google Scholar
• Hefti F, Jundt G. Langerhans cell histiocytosis. Orthopade. 1995;24(1):73–81.
   PubMed Web of Science ®Google Scholar
• Arnaud L, Hervier B, Néel A, et al. CNS involvement and treatment with interferon-alpha are independent prognostic factors in Erdheim–Chester disease: a multicenter survival analysis of 53 patients. Blood. 2011;117(10):2778–2782.
   PubMed Web of Science ®Google Scholar
• Haroche J, Arnaud L, Cohen-Aubart F, et al. Erdheim–Chester disease. Curr Rheumatol Rep. 2014;16(4):412.
   PubMed Web of Science ®Google Scholar
• Karcioglu ZA, Sharara N, Boles TL, et al. Orbital xanthogranuloma: clinical and morphologic features in eight patients. Ophthal Plast Reconstr Surg. 2003;19(5):372–381.
   PubMed Web of Science ®Google Scholar
• Pautas E, Chérin P, Pelletier S, et al. Cerebral Erdheim–Chester disease: report of two cases with progressive cerebellar syndrome with dentate abnormalities on magnetic resonance imaging. J Neurol Neurosurg Psychiatry. 1998;65(4):597–599.
   PubMed Web of Science ®Google Scholar
• Killu AM, Liang JJ, Jaffe AS. Erdheim–Chester disease with cardiac involvement successfully treated with anakinra. Int J Cardiol. 2013;167(5):e115–e117.
   PubMed Web of Science ®Google Scholar
• Arnaud L, Pierre I, Beigelman-Aubry C, et al. Pulmonary involvement in Erdheim–Chester disease: a single-center study of thirty-four patients and a review of the literature. Arthritis Rheum. 2010;62(11):3504–3512.
   PubMed Web of Science ®Google Scholar
• Arnaud L, Gorochov G, Charlotte F, et al. Systemic perturbation of cytokine and chemokine networks in Erdheim–Chester disease: a single-center series of 37 patients. Blood. 2011;117(10):2783–2790.
   PubMed Web of Science ®Google Scholar
• Steňová E, Steňo B, Povinec P, et al. FDG-PET in the Erdheim–Chester disease: its diagnostic and follow-up role. Rheumatol Int. 2012;32(3):675–678.
   PubMed Web of Science ®Google Scholar
• Braiteh F, Boxrud C, Esmaeli B, et al. Successful treatment of Erdheim–Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alpha. Blood. 2005;106(9):2992–2994.
   PubMed Web of Science ®Google Scholar
• Hervier B, Haroche J, Arnaud L, et al. Association of both Langerhans cell histiocytosis and Erdheim–Chester disease linked to the BRAFV600E mutation. Blood. 2014;124(7):1119–1126.
   PubMed Web of Science ®Google Scholar
• Go H, Jeon YK, Huh J, et al. Frequent detection of BRAF(V600E) mutations in histiocytic and dendritic cell neoplasms. Histopathology. 2014;65(2):261–272.
   PubMed Web of Science ®Google Scholar
• Diamond EL, Durham BH, Haroche J, et al. Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov. 2016;6(2):154–165.
   PubMed Web of Science ®Google Scholar
• Haroche J, Cohen-Aubart F, Emile J-F, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim–Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood. 2013;121(9):1495–1500.
   PubMed Web of Science ®Google Scholar